Skip to content

Nektar Therapeutics

US · NKTR #3017 by market cap Listed 1970
30.20 -2.34 -7.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Rating change
    Leerink Partners Initiates Nektar Therapeutics at Outperform, $130 Price Target
    MT Newswires · 2026/10/12
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR), Roche Holding AG (OtherRHHVF) and Henry Schein (HSIC)
    TipRanks · 2026/10/12
  • Rating change
    Leerink Partners Initiates Coverage On Nektar Therapeutics With Outperform Rating, Announces Price Target of $130
    Benzinga · 2026/10/12
  • Rating change
    UBS Initiates Nektar Therapeutics(NKTR.US) With Hold Rating, Announces Target Price $53
    Market Newswire · 2026/10/12
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and Nektar Therapeutics (NKTR)
    TipRanks · 2026/10/12
  • Rating change
    Nektar Therapeutics Initiated at Outperform by Leerink Partners
    Dow Jones · 2026/10/12
  • Rating change
    Nektar Therapeutics Price Target Announced at $53.00/Share by UBS
    Dow Jones · 2026/10/12
  • Nektar Therapeutics Q3 Loss Narrows, Revenue Falls
    MT Newswires · 2026/11/13
  • Rating change
    UBS Maintains Nektar Therapeutics(NKTR.US) With Hold Rating, Maintains Target Price $53
    Market Newswire · 2026/10/12
  • Company notice
    Nektar Therapeutics | 8-K: Nektar Therapeutics Announces Third Quarter 2026 Financial Results
    SEC · 2026/11/13
  • Company notice
    Nektar Therapeutics | SCHEDULE 13G: Others
    SEC · 2026/11/10
  • Company notice
    Nektar Therapeutics | 10-Q: Quarterly report
    SEC · 2026/11/14
  • Rating change
    Nektar Therapeutics Initiated at Neutral by UBS
    Dow Jones · 2026/10/12
  • Company notice
    Nektar Therapeutics | 8-K: Current report
    SEC · 2026/11/13
  • Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $192
    Market Newswire · 2026/11/13
  • Wedbush Cuts Price Target on Nektar Therapeutics to $40 From $50, Keeps Neutral Rating
    MT Newswires · 2026/11/13
  • Rating change
    Nektar Therapeutics Price Target Announced at $130.00/Share by Leerink Partners
    Dow Jones · 2026/10/12
  • Wedbush Maintains Nektar Therapeutics(NKTR.US) With Hold Rating, Cuts Target Price to $40
    Market Newswire · 2026/11/13
  • Company notice
    Nektar Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
    SEC · 2026/10/21
  • Rating change
    BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
    Benzinga · 2026/10/10
  • Company notice
    Nektar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director GREER R SCOTT
    SEC · 2026/9/26
  • Rating change
    Nektar Therapeutics Initiated at Market Perform by Raymond James
    Dow Jones · 2026/10/9
  • Company notice
    Nektar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director WHITFIELD ROY A
    SEC · 2026/9/26
  • Rating change
    Nektar Therapeutics Price Target Maintained With a $178.00/Share by BTIG
    Dow Jones · 2026/10/10
  • Company notice
    Nektar Therapeutics | 8-K: Current report
    SEC · 2026/10/1

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:35 · For reference only, not investment advice and not tailored to your situation.

Nektar Therapeutics discussion 0 comments

Add a comment